ReviewPharmaceuticals (Basel, Switzerland)2021

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.

Mariya Yordanova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.